Research and Development Strategy of Classical Formula Compound Preparation

Yan LIU; Jun ZHANG; Shi-lin CHEN; Jing-tang CHEN; Dong-xue LI; An LIU

doi:10.13422/j.cnki.syfjx.20192445

您当前的位置：

首页 >

文章列表页 >

Research and Development Strategy of Classical Formula Compound Preparation

Academic Discussion | 更新时间：2021-02-09

- Research and Development Strategy of Classical Formula Compound Preparation
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 24, Pages: 166-172(2019)
- 作者机构：
  
  1.中国中医科学院　中药研究所，北京　 100700
  2.中国生物技术发展中心，北京　 100039
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192445
  CLC： R2; R1; R289
- Published：20 December 2019，
  
  Published Online：09 September 2019，
  
  Received：06 September 2019，
- 稿件说明：
扫描看全文
Yan LIU, Jun ZHANG, Shi-lin CHEN, et al. Research and Development Strategy of Classical Formula Compound Preparation. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(24):166-172(2019)
DOI：

Yan LIU, Jun ZHANG, Shi-lin CHEN, et al. Research and Development Strategy of Classical Formula Compound Preparation. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(24):166-172(2019) DOI： 10.13422/j.cnki.syfjx.20192445.

摘要

尽管国家颁布了100首经典名方目录，但是从经典名方开发成复方制剂依然面临着很多困惑和抉择。本文从成药性评价、工业化考量和临床定位三个角度阐述了经典名方复方制剂的研制策略。成药性评价主要考虑药学和临床前安全性两部分内容，应着重把握物质基准、用药剂量、“有毒”药味、临床使用等因素影响。工业化考量需重点关注如何采用现代工业化方法，制备出与物质基准等质的现代制剂。采用提取物投料也许是解决饮片利用率不高、工业化优势不能充分发挥等问题的有效方法。临床定位应明确主效应，兼顾次效应，重视负效应，考虑临床价值的高低。文中提出的研究思路和若干策略，旨在为企业及研究者挑选适宜品种进行研发布局提供参考，以期抛砖引玉，更好的推进经典名方复方制剂开发。

Abstract

Although the country has promulgated a list of 100 classical famous formula

there are still many confusions and choices in the development of compound preparations from classical prescriptions. In this paper

the development strategy of classical formula compound preparation was elaborated from three aspects: the evaluation of draggability

the consideration of industrialization and the clinical orientation. The draggability evaluation includes pharmacy and preclinical safety. It should focus on the factors such as substance benchmark

dosage

toxic herbal medicines

clinical use and so on. Industrialization considerations need to focus on how to use modern industrialization methods to prepare modern compound preparations with the same quality as material benchmarks. The use of extracts may be an effective way to solve the problems of low utilization rate of decoction pieces and inadequate industrial advantages. Clinical orientation should be clear about the main effect

take into account the secondary effect

pay attention to the negative effect

and consider the level of clinical value. A series of corresponding development strategies and ideas are proposed in order to provide references for enterprises and researchers who select and layout classical famous formula

to promote the development of classical prescription compound preparation.

关键词

经典名方复方制剂研发策略成药性工业化临床定位

Keywords

classical famous formulaecompound preparationresearch and development strategiesevaluation of draggabilityindustrializationclinical orientation

references

国家中医药管理局．古代经典名方目录(第一批)[EB/OL]．http://kjs.satcm.gov.cn/zhengcewenjian/2018-04-16/7107.html，2018-04-13/2019-08-18．

国家药品监督管理局．国家药品监督管理局关于发布古代经典名方中药复方制剂简化注册审批管理规定的公告(2018年第27号)[EB/OL]．http://www.sdaqh.gov.cn/html/201864/n191825018.html，2018/2019-08-18．

国家药监局综合司．国家药监局综合司公开征求古代经典名方中药复方制剂及其物质基准申报资料要求(征求意见稿)意见[EB/OL]．http://www.nmpa.gov.cn/WS04/CL2101/335926.html，2019-03-22/2019-08-18．

杨洪军，黄璐琦．经典名方的研发—中医药传承发展的突破口之一[J]．中国现代中药，2018，20(7)：775-779．

陈畅，程锦堂，刘安．经典名方研发策略[J]．中国中药杂志，2017，42(9)：1814-1818．

王智民，刘菊妍，刘晓谦，等．谈经典名方的化学、生产和质量控制研发和监管[J]．中国中药杂志，2017，42(10)：1819-1824．

梁爱华，韩佳寅，陈士林，等．中药经典名方的质量与安全性考量[J]．中国食品药品监管，2018，173(6)：4-10．

施铮，陈仁寿，李陆杰，等．经典名方研发的几个关键问题刍议[J]．南京中医药大学学报，2019，35(4)：366-369．

刘艳，章军，杨林勇，等．经典名方物质基准研制策略及关键问题分析[J]．中国实验方剂学杂志，2019，doi: 10.13422/j.cnki.syfjx.20192150http://doi.org/10.13422/j.cnki.syfjx.20192150．

卢嘉锡，丘光明．中国科学技术史：度量衡卷[M]．北京：科学出版社，2001．

傅延龄，宋佳，张林．经方本原剂量问题源流[J]．北京中医药大学学报，2013，36(5)：293-296．

姬航宇．《伤寒论》本源药物剂量探索—仝小林教授应用经方本源剂量治疗糖尿病的经验总结[D]．北京：北京中医药大学，2009．

李飞．方剂学[M]．2版．北京：人民卫生出版社，2011．

夏青，张晓昕，徐柯心，等．《中华人民共和国药典》2015版收载的有毒中药毒性研究概况[J]．环球中医药，2017，10(3)：377-384．

车宏伟，侯飞，杨海宁，等．首批国家公布的经典名方剖析[J]．亚太传统医药，2019，15(4)：173-175．

游云，黄芳华，韩玲．《中华人民共和国药典》收录孕妇禁用和慎用中药材生殖毒性研究进展[J]．中国药理学与毒理学杂志，2018，32(5)：364-370．

康丽，高慧，王璐，等．中成药不良反应报告中不合理用药回顾性分析[J]．临床医学研究与实践，2017，2(27)：101-102．

王东喆，章军，张丽艳，等．基于动态过程的提取工艺优化方法研究[J]．中国中药杂志，2012，37(10)：1388-1391．

程建明，颜媛媛，王琪，等．经典名方产品开发政策及制备工艺探析[J]．南京中医药大学学报，2019，35(4)：370-372．

周欣欣，罗贤强，张俊清，等．中药散剂研究的现状[J]．海南医学，2019，30(3)：392-394．

陆泽俭．中药膏剂介绍[C]．首届全国膏方理论与临床应用学术研讨会论文集，江阴，2009：42-46．

邹新权．如何有效提升中药生产企业成本控制质量[J]．财经界：学术版，2015，doi: 10.16266/j.cnki.cn11-4098/f.2015.10.063http://doi.org/10.16266/j.cnki.cn11-4098/f.2015.10.063．

商洪才，张伯礼，李幼平．上市后中成药再评价临床定位的原则和方法——基于循证医学的理念[J]．中西医结合学报，2008，6(9)：887-890．

刘炳林．从临床角度看中药新药适应症的定位[J]．中药新药与临床药理，2011，22(2)：226-227．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Textual Research of Classical Prescription Da Jianzhongtang

Relation Textual Research Between Effect Variation and Dosage of Famous Classical Formula Kaixinsan

Textual Research on Ancient Literature of Classical Prescription Kaixinsan and Its Associated Prescription

Research on Development Strategies of Traditional Chinese Medicine Enterprises Based on SWOT Analysis

Overview of Famous Classical Formulas and Discussion on Its Exploitation

Related Author

Yin XU

Shan ZHOU

Guo-zheng LI

Li-yan YANG

Yu-li LI

Teng-da YI

Zhi-qiang TAN

Rui-ling YANG

Related Institution

Haikou Hospital of Traditional Chinese Medicine

The First Hospital of Hunan University of Chinese Medicine

Hunan University of Chinese Medicine

Bozhou District Hospital of Traditional Chinese Medicine（TCM）

Kunming Municipal Hospital of TCM

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰